Guru Fundamental Report for INSM

INSMED INC (INSM), a large-cap biotechnology growth stock, scored only 43% against Validea's Benjamin Graham deep value investment model, significantly below the 80% threshold for investor interest. The analysis revealed INSM fails key value criteria including sales, long-term EPS growth, P/E, and price/book ratios, indicating it does not align with traditional deep value investment principles despite passing certain debt and liquidity checks.

Analysis

Insmed Inc. (INSM), a large-cap growth stock in the biotechnology sector, demonstrates a significant misalignment with traditional deep value investment principles, according to a Validea report based on Benjamin Graham's methodology. The company received a score of only 43%, substantially below the 80% threshold that typically signals interest from this strategy. The analysis reveals specific fundamental weaknesses from a value perspective, with INSM failing on key metrics including sales, long-term EPS growth, P/E ratio, and price/book ratio. This poor performance on valuation and growth criteria is the primary driver of the moderately negative sentiment score of -0.6 associated with the stock. Conversely, the company does exhibit balance sheet strength, passing tests for its current ratio and its level of long-term debt in relation to net current assets, indicating a solid liquidity position.

Key Decisions for Investors

• Investors with a deep value mandate should view this analysis as a strong negative signal, as INSM fails on core valuation metrics central to a Graham-style strategy.
• Growth-oriented investors should recognize that this value-centric report does not assess the company's growth catalysts, but the failure on sales and long-term EPS growth criteria could still be a point of concern requiring further due diligence.
• The analysis highlights a potential valuation risk, and it would be prudent for current and potential investors to monitor the stock's high multiples relative to its fundamental performance.
• Consider the company's sound financial health, evidenced by its strong current ratio and manageable debt, as a potential mitigating factor against its unfavorable valuation metrics.